EZH2 and head and neck squamous cell carcinoma: Thus, our preclinical study highlighted the potential of combined EZH2 inhibition and anti-PD-1 treatment in improving the efficacy and clinical outcome of immunotherapy in patients with HNSCC (Fig. 1).